# Narration and storyboard draft: Laetrile / Amygdalin as Cancer Treatment

Authored draft, approximately 60–90 seconds; no rendered video claimed.

Laetrile and amygdalin are promoted as selective cancer treatments, but the examined human evidence does not demonstrate a meaningful clinical benefit. The1982 study was nonrandomized and treated178 patients with a metabolic programme; it must not be called a randomized trial or described as having literally zero responses. Earlier selected case records included judged responses, but selection and concurrent treatment prevented reliable attribution. Route matters: intravenous exposure behaves differently from oral dosing, which can generate systemic cyanide, especially with interacting foods. Prescribed oral tablets have caused serious poisoning. Modern research does contain positive matched-cell and animal findings, including engineered carriers and enzyme activation. Those are experimental platforms, not confirmation of historical patient regimens. Under HSEF v5.3, the registered human-treatment benefit is unsupported at Α. Partial laboratory and experimental selectivity remains Γ in a separate subclaim, and route-dependent cyanide harm reaches Ζ in the competing model. These are separate findings, rather than a patient recommendation. Before any new platform reaches clinical testing, it must demonstrate selective activity at measured attainable exposure, a normal-organ safety margin and credible tumour control. Effective cancer care should be preserved.

1. Show the exact claim, grade and confidence.
2. Show selected publication milestones; label experimental systems and clinical endpoints.
3. Contrast the strongest result with its source-specific limitation.
4. End with the boundary experiment and primary-source links.

Use authored schematics; do not depict Consensus meters as causal confidence or reproduce publisher graphics without appropriate permission.